STOCK TITAN

Tenet Reports Second Quarter 2023 Results; Raises 2023 Outlook

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Tenet Healthcare Corporation (Tenet) announced its results for the quarter ended June 30, 2023, showing positive momentum with robust volume and revenue growth. Net income from continuing operations available to common shareholders in Q2 2023 was $123 million, or $1.15 per diluted share, compared to $38 million, or $0.35 per diluted share, in Q2 2022. Consolidated Adjusted EBITDA in Q2 2023 was $843 million. FY 2023 Adjusted EBITDA Outlook increased, now expected to be in the range of $3.310 billion to $3.460 billion.
Positive
  • Net income from continuing operations increased significantly compared to Q2 2022
  • Consolidated Adjusted EBITDA in Q2 2023 was $843 million
  • FY 2023 Adjusted EBITDA Outlook increased
Negative
  • None.
  • Net income from continuing operations available to common shareholders in second quarter 2023 was $123 million, or $1.15 per diluted share
  • Adjusted diluted earnings per share from continuing operations1 was $1.44 in second quarter 2023
  • Consolidated Adjusted EBITDA1 in second quarter 2023 was $843 million, including $8 million of grant income
  • Second quarter 2023 Ambulatory Care Adjusted EBITDA of $369 million increased 16.4% over second quarter 2022 excluding grant income
  • Same-facility system-wide ambulatory surgical cases increased 6.6% versus second quarter 2022; Same-hospital admissions increased 3.0% versus second quarter 2022, with non-Covid admissions up 5%
  • FY 2023 Adjusted EBITDA Outlook increased, now expected to be in the range of $3.310 billion to $3.460 billion

DALLAS--(BUSINESS WIRE)-- Tenet Healthcare Corporation (Tenet) (NYSE: THC) today announced its results for the quarter ended June 30, 2023.

"We have continued positive momentum through the second quarter with robust same facility volume and revenue growth in our ambulatory care segment as well as continued strength in our hospital segment," said Saum Sutaria, M.D., Chief Executive of Tenet. "Our strategic growth initiatives and operating discipline helped drive these results as we expand our patient-centered care capabilities in the communities we serve."

Tenet’s results for second quarter 2023 versus second quarter 2022 are as follows:

 

Three Months Ended June 30,

Six Months Ended June 30,

($ in millions, except per share results)

2023

2022

2023

2022

Net operating revenues

$5,082

$4,638

$10,103

$9,383

Net income available to Tenet common shareholders from continuing operations

$123

$38

$266

$177

Net income available to Tenet common shareholders from continuing operations per diluted share

$1.15

$0.35

$2.47

$1.63

Adjusted EBITDA1 excluding grant income

$835

$749

$1,664

$1,631

Adjusted EBITDA1

$843

$843

$1,675

$1,731

Adjusted diluted earnings per share from continuing operations1

$1.44

$1.48

$2.87

$3.33

  • Net income from continuing operations available to the Company’s common shareholders in the second quarter 2023 was $123 million, or $1.15 per diluted share, versus $38 million, or $0.35 per diluted share, in second quarter 2022.
  • Second quarter 2023 included COVID-related stimulus grant income of $8 million pre-tax ($6 million after-tax, or $0.06 per diluted share) versus $94 million pre-tax ($71 million after-tax, or $0.65 per diluted share) in second quarter 2022.
  • The Company recognized additional income tax expense for the three months ended June 30, 2023 of approximately $23 million, or $0.22 per diluted share, and $45 million, or $0.41 per diluted share for the three months ended June 30, 2022, as a result of interest expense limitation tax regulations.
  • Adjusted EBITDA1 excluding grant income in second quarter 2023 was $835 million compared to $749 million in second quarter 2022, reflecting strong volume growth in our Ambulatory Care and Hospital Operations segments, and improved contract labor costs. The Company believes this strong volume growth is due in part to patient care deferred as a result of the pandemic. Second quarter 2022 results included the adverse impacts associated with a cybersecurity incident.

Balance Sheet and Cash Flows

  • Cash flows provided by operating activities for the six months ended June 30, 2023 were $1.047 billion versus $347 million for the six months ended June 30, 2022 (or $822 million excluding $475 million of repayments associated with Medicare advances).
  • The Company produced free cash flow1 of $680 million for the six months ended June 30, 2023 versus $40 million for the six months ended June 30, 2022 (or $515 million excluding the repayment of Medicare advances).
  • In the three months ended June 30, 2023, the Company repurchased 579,637 shares of common stock for $40 million. In the six months ended June 30, 2023, the Company repurchased 1,485,983 shares of common stock for $90 million.
  • In June 2023, the Company completed a private placement of $1.350 billion in aggregate principal amount of newly issued 6.750% senior secured first lien notes maturing in 2031. The Company used the net proceeds from the sale of the notes, after payment of fees and expenses, to finance, together with cash on hand, the redemption of all $1.345 billion aggregate principal amount then outstanding of its 4.625% senior secured notes due 2024. The Company now has no significant debt maturities until 2026.
  • The Company’s ratio of net debt to Adjusted EBITDA1 was 4.14x at June 30, 2023 compared to 4.19x at March 31, 2023 and 4.10x at December 31, 2022.
  • The Company had no outstanding borrowings on its $1.5 billion line of credit as of June 30, 2023.

Ambulatory Care (Ambulatory) Segment

Tenet’s Ambulatory business segment is comprised of the operations of United Surgical Partners International (USPI). As of June 30, 2023, USPI had interests in 455 ambulatory surgery centers (312 consolidated) and 24 surgical hospitals (eight consolidated) in 35 states. For all periods prior to June 30, 2022, the Company owned 95% of the voting stock of USPI and now owns 100%.

 

Three Months Ended June 30,

Six Months Ended June 30,

Ambulatory segment results ($ in millions)

2023

2022

2023

2022

Revenues

 

 

 

 

Net operating revenues

$942

$771

$1,847

$1,509

Same-facility system-wide net patient service revenues2

$1,721

$1,568

$3,358

$3,065

Volume Changes versus the Prior-Year Period

 

 

 

 

Same-facility system-wide surgical cases2

6.6%

(0.9)%

7.2%

3.3%

Same-facility system-wide surgical cases on same-business day basis2

6.6%

(0.9)%

7.2%

2.4%

Adjusted EBITDA, Margins and Noncontrolling Interest (NCI)

 

 

 

 

Adjusted EBITDA excluding grant income

$369

$317

$709

$597

Adjusted EBITDA

$370

$319

$710

$601

Adjusted EBITDA margin excluding grant income

39.2%

41.1%

38.4%

39.6%

Adjusted EBITDA margin

39.3%

41.4%

38.4%

39.8%

Adjusted EBITDA less facility-level NCI excluding grant income

$231

$209

$445

$395

Adjusted EBITDA less facility-level NCI

$231

$210

$445

$397

Adjusted EBITDA less total NCI excluding grant income

$231

$204

$445

$386

Adjusted EBITDA less total NCI

$231

$205

$445

$388

  • Second quarter 2023 net operating revenues increased 22.2% compared to second quarter 2022 driven by strong same-facility net surgical case growth, acquisitions and opening of new facilities, service line growth and improved pricing yield.
  • Surgical business same-facility system-wide net patient service revenues increased 9.8% in second quarter 2023 compared to second quarter 2022, with cases up 6.6% and net revenue per case up 2.9%.
  • Second quarter 2023 Adjusted EBITDA excluding grant income increased 16.4% relative to second quarter 2022, due to strong same-facility system-wide surgical case growth, contributions from acquisitions and de novo facilities, improved pricing yield, and effective expense management.
  • Adjusted EBITDA margin excluding grant income in the second quarter 2023 declined relative to second quarter 2022 primarily due to higher other operating expenses partially offset by improved salaries, wages and benefits.

Hospital Operations and Other (Hospital) Segment

Tenet’s Hospital business segment is primarily comprised of acute care and specialty hospitals, imaging centers, ancillary outpatient facilities, micro-hospitals and physician practices.

 

Three Months Ended June 30,

Six Months Ended June 30,

Hospital segment results ($ in millions)

2023

2022

2023

2022

Revenues

 

 

 

 

Net operating revenues (prior to inter-segment eliminations)

$3,922

$3,645

$7,821

$7,443

Grant income

$7

$92

$10

$96

Same-hospital net patient service revenues3

$3,590

$3,344

$7,137

$6,851

Same-Hospital Volume Changes versus the Prior-Year Period

 

 

 

 

Admissions

3.0%

(8.1)%

3.6%

(6.4)%

Adjusted admissions4

3.2%

(5.3)%

4.9%

(3.5)%

Outpatient visits (including outpatient ER visits)

(1.3)%

(10.0)%

(0.6)%

(4.7)%

Emergency Room visits (inpatient and outpatient)

0.4%

3.8%

2.5%

8.5%

Hospital surgeries

(0.1)%

(8.0)%

1.1%

(4.3)%

Adjusted EBITDA

 

 

 

 

Adjusted EBITDA excluding grant income

$381

$339

$783

$849

Adjusted EBITDA

$388

$431

$793

$945

Adjusted EBITDA margin excluding grant income

9.7%

9.3%

10.0%

11.4%

Adjusted EBITDA margin

9.9%

11.8%

10.1%

12.7%

  • Second quarter 2023 net operating revenues increased 7.6% from second quarter 2022 primarily due to increased adjusted admissions, improved pricing yield, and the adverse impacts associated with a cybersecurity incident in the second quarter of 2022.
  • Same-hospital net patient service revenue per adjusted admission increased 4.0% year-over-year for second quarter 2023 primarily due to improved pricing yield and our focus on growing higher acuity services. COVID admissions were 2% of total admissions in the second quarter 2023 versus 3% in the second quarter 2022. Second quarter non-COVID inpatient admissions increased 5% over second quarter 2022.
  • Adjusted EBITDA excluding grant income in second quarter 2023 was $381 million compared to $339 million in second quarter 2022, reflecting strong adjusted admissions growth and improved contract labor costs, partially offset by higher other operating expenses. Second quarter 2022 results included the adverse impacts associated with a cybersecurity incident.

Conifer Segment

Tenet’s Conifer business segment provides comprehensive end-to-end and focused-point business process services, including hospital and physician revenue cycle management, patient communications and engagement support and value-based care solutions to hospitals, health systems, physician practices, employers, and other clients.

 

Three Months Ended
June 30,

Six Months Ended
June 30,

Conifer segment results ($ in millions)

2023

2022

2023

2022

Net operating revenues

$323

$333

$647

$657

Adjusted EBITDA

$85

$93

$172

$185

Adjusted EBITDA margin

26.3%

27.9%

26.6%

28.2%

  • Second quarter 2023 net operating revenues declined 3.0% compared to second quarter 2022 reflecting previously announced contract changes with Tenet hospitals.
  • Second quarter 2023 Adjusted EBITDA and Adjusted EBITDA margin declined compared to second quarter 2022 reflecting the aforementioned contract changes.

2023 Outlook1

Tenet’s Outlook for full year 2023 (consolidated and by segment) and third quarter 2023 follows:

CONSOLIDATED ($ in millions, except per share amounts)

FY 2023 Outlook

Third Quarter
2023 Outlook

Net operating revenues

$20,100 to $20,500

$4,900 to $5,100

Income from continuing operations available to Tenet common stockholders

$447 to $582

$75 to $120

Adjusted EBITDA

$3,310 to $3,460

$775 to $825

Adjusted EBITDA margin

16.5% to 16.9%

15.8% to 16.2%

Diluted income per common share from continuing operations

$4.19 to $5.48

$0.71 to $1.13

Adjusted net income from continuing operations

$550 to $640

$100 to $135

Adjusted diluted earnings per share from continuing operations

$5.18 to $6.03

$0.94 to $1.28

Equity in earnings of unconsolidated affiliates

$200 to $220

$45 to $55

Depreciation and amortization

$850 to $875

$210 to $220

Interest expense

$895 to $905

$220 to $230

Income tax expense5

$315 to $335

$65 to $75

Net income available to NCI

$660 to $700

$160 to $170

Weighted average diluted common shares

~105 million

~105 million

NCI cash distributions

$565 to $605

 

Net cash provided by operating activities

$1,775 to $2,075

 

Adjusted net cash provided by operating activities

$1,925 to $2,175

 

Capital expenditures

$675 to $725

 

Free cash flow

$1,100 to $1,350

 

Adjusted free cash flow – continuing operations

$1,250 to $1,450

 

Ambulatory Segment ($ in millions)

FY 2023 Outlook

Net operating revenues

$3,725 to $3,825

Adjusted EBITDA

$1,490 to $1,530

Total NCI (Facility level)

$545 to $565

Adjusted EBITDA less total NCI

$945 to $965

Changes versus prior year6:

 

Surgical cases volumes

Up 5.0% to 6.0%

Net revenues per surgical case

Up 2.0% to 3.0%

Hospital Segment ($ in millions)

FY 2023 Outlook

Net operating revenues (prior to inter-segment eliminations)

$15,540 to $15,790

Adjusted EBITDA

$1,490 to $1,590

NCI

$25 to $40

Changes versus prior year6:

 

Inpatient admissions

Up 2.0% to 4.0%

Adjusted admissions

Up 2.5% to 4.5%

Conifer Segment ($ in millions)

FY 2023 Outlook

Net operating revenues

$1,285 to $1,335

Adjusted EBITDA

$330 to $340

NCI

$90 to $95

Management’s Webcast Discussion of Results

Tenet management will discuss the Company’s second quarter 2023 results in a webcast scheduled for 5:00 p.m. Eastern Time (4:00 p.m. Central Time) on July 31, 2023. Investors can access the webcast through the Company’s website at www.tenethealth.com/investors.

The slide presentation associated with the webcast referenced above, a copy of this earnings press release, and a related supplemental financial disclosures document will be available on the Company’s Investor Relations website on July 31, 2023.

Cautionary Statement

This release contains “forward-looking statements” - that is, statements that relate to future, not past, events. In this context, forward-looking statements often address the Company’s expected future business and financial performance and financial condition, and often contain words such as “expect,” “anticipate,” “assume,” “believe,” “budget,” “estimate,” “forecast,” “intend,” “plan,” “predict,” “project,” “seek,” “see,” “target,” or “will.” Forward-looking statements by their nature address matters that are, to different degrees, uncertain, especially with regards to developments related to COVID-19. Particular uncertainties that could cause the Company’s actual results to be materially different than those expressed in the Company’s forward-looking statements include, but are not limited to the impact of the COVID-19 pandemic, and other factors disclosed under “Forward-Looking Statements” and “Risk Factors” in our Form 10-K for the year ended December 31, 2022 and other filings with the Securities and Exchange Commission.

Footnotes

  1. Tables and discussions throughout this earnings release include certain financial measures, including those related to our second quarter and full year 2023 Outlook, that are not in accordance with accounting principles generally accepted in the United States of America (GAAP). Reconciliations of GAAP measures to the Adjusted (non-GAAP) measures used are detailed in Tables #1-6 included at the end of this earnings release. Management’s reasoning for the use of these non-GAAP measures and descriptions of the various non-GAAP measures are included in the Non-GAAP Financial Measures section of this earnings release.
  2. Same-facility system-wide revenues and statistical information include the results of the facilities in which the Ambulatory segment has an investment that are not consolidated by Tenet. To help analyze the segment’s results of operations, management uses system-wide measures, which include revenues and cases of both consolidated and unconsolidated facilities.
  3. For 2023, same-hospital revenues and statistical data include those for hospitals and hospital-affiliated outpatient centers operated by the Company’s Hospital segment continuously from January 1, 2022 through June 30, 2023. Amounts associated with physician practices are excluded.
  4. Adjusted admissions represent actual patient admissions adjusted to include outpatient services provided by facilities in our Hospital segment by multiplying actual patient admissions by the sum of gross inpatient revenues and outpatient revenues, then dividing that result by gross inpatient revenues.
  5. Income tax expense is calculated by multiplying 24% (the federal corporate tax rate of 21% plus an estimate of state taxes) by the sum of: pretax income less GAAP facility level NCI expense plus permanent differences, and non-deductible interest expense.
  6. Change versus prior year is presented on a same-facility system-wide basis for USPI Ambulatory surgical cases and on a same-hospital basis for hospital statistics.

About Tenet Healthcare

Tenet Healthcare Corporation (NYSE: THC) is a diversified healthcare services company headquartered in Dallas. Our care delivery network includes United Surgical Partners International, the largest ambulatory platform in the country, which operates or has ownership interests in more than 475 ambulatory surgery centers and surgical hospitals. We also operate 61 acute care and specialty hospitals, approximately 110 other outpatient facilities, a network of leading employed physicians and a global business center in Manila, Philippines. Our Conifer Health Solutions subsidiary provides revenue cycle management and value-based care services to hospitals, health systems, physician practices, employers and other clients. Across the Tenet enterprise, we are united by our mission to deliver quality, compassionate care in the communities we serve. For more information, please visit www.tenethealth.com.

Non-GAAP Financial Measures

The Company believes the non-GAAP measures described below are useful to investors and analysts because they present additional information on the Company’s financial performance. Investors, analysts, Company management and the Company’s Board of Directors utilize these non-GAAP measures, in addition to GAAP measures, to track the Company’s financial and operating performance and compare the Company’s performance to its peer companies, which use similar non-GAAP financial measures in their presentations and earnings releases. The Human Resources Committee of the Company’s Board of Directors also uses certain of these measures to evaluate management’s performance for the purpose of determining incentive compensation. Additional information regarding the purpose and utility of specific non-GAAP measures used in this release is set forth below.

  • Adjusted EBITDA is defined by the Company as net income available (loss attributable) to Tenet common shareholders before (1) the cumulative effect of changes in accounting principles, (2) net loss attributable (income available) to noncontrolling interests, (3) income (loss) from discontinued operations, net of tax, (4) income tax benefit (expense), (5) gain (loss) from early extinguishment of debt, (6) other non-operating income (expense), net, (7) interest expense, (8) litigation and investigation benefit (costs), net of insurance recoveries, (9) net gains (losses) on sales, consolidation and deconsolidation of facilities, (10) impairment and restructuring charges and acquisition-related costs, (11) depreciation and amortization and (12) income (loss) from divested and closed businesses (i.e., health plan businesses). Litigation and investigation costs excluded do not include ordinary course of business malpractice and other litigation and related expenses.
  • Adjusted diluted earnings (loss) per share from continuing operations is defined by the Company as Adjusted net income available (loss attributable) from continuing operations to Tenet common shareholders, divided by the weighted average diluted shares outstanding in the reporting period.
  • Adjusted net income available (loss attributable) from continuing operations to Tenet common shareholders is defined by the Company as net income available (loss attributable) to Tenet common shareholders before (1) income (loss) from discontinued operations, net of tax, (2) gain (loss) from early extinguishment of debt, (3) litigation and investigation benefit (costs), net of insurance recoveries, (4) net gains (losses) on sales, consolidation and deconsolidation of facilities, (5) impairment and restructuring charges and acquisition-related costs, (6) income (loss) from divested and closed businesses (i.e., health plan businesses) and (7) the associated impact of these items on taxes and noncontrolling interests. Litigation and investigation costs excluded do not include ordinary course of business malpractice and other litigation and related expenses.
  • Free Cash Flow is defined by the Company as (1) net cash provided by (used in) operating activities, less (2) purchases of property and equipment for continuing operations.
  • Adjusted Free Cash Flow is defined by the Company as (1) Adjusted net cash provided by (used in) operating activities from continuing operations, less (2) purchases of property and equipment from continuing operations.
  • Adjusted net cash provided by (used in) operating activities is defined by the Company as cash provided by (used in) operating activities prior to (1) payments for restructuring charges, acquisition-related costs and litigation costs and settlements, and (2) net cash provided by (used in) operating activities from discontinued operations.

The Company believes that Adjusted EBITDA is a useful measure, in part, because certain investors and analysts use both historical and projected Adjusted EBITDA, in addition to other GAAP and non-GAAP measures, as factors in determining the estimated fair value of shares of the Company’s common stock. Company management also regularly reviews the Adjusted EBITDA performance for each operating segment. The Company does not use Adjusted EBITDA to measure liquidity, but instead to measure operating performance.

The Company uses, and believes investors use, Free Cash Flow and Adjusted Free Cash Flow as supplemental non-GAAP measures to analyze cash flows generated from the Company’s operations. The Company believes these measures are useful to investors in evaluating its ability to fund distributions paid to noncontrolling interests or for acquisitions, purchasing equity interests in joint ventures or repaying debt.

These non-GAAP measures may not be comparable to similarly titled measures reported by other companies. Because these measures exclude many items that are included in the Company’s financial statements, they do not provide a complete measure of the Company’s operating performance. For example, the Company’s definitions of Free Cash Flow and Adjusted Free Cash Flow do not include other important uses of cash including (1) cash used to purchase businesses or joint venture interests, or (2) any items that are classified as Cash Flows from Financing Activities on the Company’s Consolidated Statement of Cash Flows, including items such as (i) cash used to repay borrowings, or (ii) distributions paid to noncontrolling interests. Accordingly, investors are encouraged to use GAAP measures when evaluating the Company’s financial performance.

See corresponding reconciliations of the non-GAAP financial measures referred to above to the most comparable GAAP financial measures in Tables #1 - 6 below.

Tenet Healthcare Corporation

Financial Statements and Reconciliations

Second Quarter Earnings Release

 

Table of Contents

Description

Page

Consolidated Statements of Operations

13

Consolidated Balance Sheets

15

Consolidated Statements of Cash Flows

16

Segment Reporting

17

Table #1 – Reconciliations of Net Income to Adjusted Net Income

18

Table #2 – Reconciliations of Net Income to Adjusted EBITDA

19

Table #3 – Reconciliations of Net Cash Provided by Operating Activities to Free Cash Flow and Adjusted Free Cash Flow

20

Table #4 – Reconciliations of Outlook Net Income to Outlook Adjusted Net Income

21

Table #5 – Reconciliations of Outlook Net Income to Outlook Adjusted EBITDA

22

Table #6 – Reconciliations of Outlook Net Cash Provided by Operating Activities to Outlook Free Cash Flow and Outlook Adjusted Free Cash Flow

23

TENET HEALTHCARE CORPORATION

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

 

(Dollars in millions, except per share amounts)

 

Three Months Ended June 30,

 

2023

 

%

 

2022

 

%

 

Change

Net operating revenues

 

$

5,082

 

 

100.0

%

 

$

4,638

 

 

100.0

%

 

9.6

%

Grant income

 

 

8

 

 

0.2

%

 

 

94

 

 

2.0

%

 

(91.5

)%

Equity in earnings of unconsolidated affiliates

 

 

54

 

 

1.1

%

 

 

54

 

 

1.2

%

 

%

Operating expenses:

 

 

 

 

 

 

 

 

 

 

Salaries, wages and benefits

 

 

2,285

 

 

45.0

%

 

 

2,126

 

 

45.8

%

 

7.5

%

Supplies

 

 

891

 

 

17.5

%

 

 

811

 

 

17.5

%

 

9.9

%

Other operating expenses, net

 

 

1,125

 

 

22.1

%

 

 

1,006

 

 

21.7

%

 

11.8

%

Depreciation and amortization

 

 

213

 

 

4.3

%

 

 

216

 

 

4.7

%

 

 

Impairment and restructuring charges, and acquisition-related costs

 

 

16

 

 

0.3

%

 

 

57

 

 

1.2

%

 

 

Litigation and investigation costs

 

 

10

 

 

0.2

%

 

 

18

 

 

0.4

%

 

 

Net gains on sales, consolidation and deconsolidation of facilities

 

 

 

 

%

 

 

(1

)

 

%

 

 

Operating income

 

 

604

 

 

11.9

%

 

 

553

 

 

11.9

%

 

 

Interest expense

 

 

(226

)

 

 

 

 

(222

)

 

 

 

 

Other non-operating income, net

 

 

6

 

 

 

 

 

 

 

 

 

 

Loss from early extinguishment of debt

 

 

(11

)

 

 

 

 

(66

)

 

 

 

 

Income from continuing operations, before income taxes

 

 

373

 

 

 

 

 

265

 

 

 

 

 

Income tax expense

 

 

(80

)

 

 

 

 

(86

)

 

 

 

 

Net income

 

 

293

 

 

 

 

 

179

 

 

 

 

 

Less: Net income available to noncontrolling interests

 

 

170

 

 

 

 

 

141

 

 

 

 

 

Net income available to Tenet Healthcare Corporation common shareholders

 

$

123

 

 

 

 

$

38

 

 

 

 

 

Earnings per share available to Tenet Healthcare Corporation common shareholders:

 

 

 

 

 

 

 

 

 

 

Basic

 

 

 

 

 

 

 

 

 

 

Continuing operations

 

$

1.21

 

 

 

 

$

0.35

 

 

 

 

 

Diluted

 

 

 

 

 

 

 

 

 

 

Continuing operations

 

$

1.15

 

 

 

 

$

0.35

 

 

 

 

 

Weighted average shares and dilutive securities outstanding

(in thousands):

 

 

 

 

 

 

 

 

 

 

Basic

 

 

101,766

 

 

 

 

 

107,790

 

 

 

 

 

Diluted

 

 

104,778

 

 

 

 

 

108,750

 

 

 

 

 

TENET HEALTHCARE CORPORATION

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

 

(Dollars in millions, except per share amounts)

 

Six Months Ended June 30,

 

2023

 

%

 

2022

 

%

 

Change

Net operating revenues

 

$

10,103

 

 

100.0

%

 

$

9,383

 

 

100.0

%

 

7.7

%

Grant income

 

 

11

 

 

0.1

%

 

 

100

 

 

1.1

%

 

(89.0

)%

Equity in earnings of unconsolidated affiliates

 

 

104

 

 

1.0

%

 

 

100

 

 

1.1

%

 

4.0

%

Operating expenses:

 

 

 

 

 

 

 

 

 

 

Salaries, wages and benefits

 

 

4,543

 

 

45.0

%

 

 

4,308

 

 

45.9

%

 

5.5

%

Supplies

 

 

1,782

 

 

17.6

%

 

 

1,596

 

 

17.0

%

 

11.7

%

Other operating expenses, net

 

 

2,218

 

 

22.0

%

 

 

1,948

 

 

20.8

%

 

13.9

%

Depreciation and amortization

 

 

430

 

 

4.2

%

 

 

419

 

 

4.5

%

 

 

Impairment and restructuring charges, and acquisition-related costs

 

 

37

 

 

0.4

%

 

 

73

 

 

0.8

%

 

 

Litigation and investigation costs

 

 

14

 

 

0.1

%

 

 

38

 

 

0.4

%

 

 

Net gains on sales, consolidation and deconsolidation of facilities

 

 

(13

)

 

(0.1

)%

 

 

 

 

%

 

 

Operating income

 

 

1,207

 

 

11.9

%

 

 

1,201

 

 

12.8

%

 

 

Interest expense

 

 

(447

)

 

 

 

 

(449

)

 

 

 

 

Other non-operating income, net

 

 

4

 

 

 

 

 

 

 

 

 

 

Loss from early extinguishment of debt

 

 

(11

)

 

 

 

 

(109

)

 

 

 

 

Income from continuing operations, before income taxes

 

 

753

 

 

 

 

 

643

 

 

 

 

 

Income tax expense

 

 

(164

)

 

 

 

 

(185

)

 

 

 

 

Income from continuing operations, before discontinued operations

 

 

589

 

 

 

 

 

458

 

 

 

 

 

Income from discontinued operations

 

 

 

 

 

 

 

1

 

 

 

 

 

Net income

 

 

589

 

 

 

 

 

459

 

 

 

 

 

Less: Net income available to noncontrolling interests

 

 

323

 

 

 

 

 

281

 

 

 

 

 

Net income available to Tenet Healthcare Corporation common shareholders

 

$

266

 

 

 

 

$

178

 

 

 

 

 

Amounts available to Tenet Healthcare Corporation common shareholders

 

 

 

 

 

 

 

 

 

 

Income from continuing operations, net of tax

 

$

266

 

 

 

 

$

177

 

 

 

 

 

Income from discontinued operations, net of tax

 

 

 

 

 

 

 

1

 

 

 

 

 

Net income available to Tenet Healthcare Corporation common shareholders

 

$

266

 

 

 

 

$

178

 

 

 

 

 

Earnings per share available to Tenet Healthcare Corporation common shareholders:

 

 

 

 

 

 

 

 

 

 

Basic

 

 

 

 

 

 

 

 

 

 

Continuing operations

 

$

2.61

 

 

 

 

$

1.64

 

 

 

 

 

Discontinued operations

 

 

 

 

 

 

 

0.01

 

 

 

 

 

 

 

$

2.61

 

 

 

 

$

1.65

 

 

 

 

 

Diluted

 

 

 

 

 

 

 

 

 

 

Continuing operations

 

$

2.47

 

 

 

 

$

1.63

 

 

 

 

 

Discontinued operations

 

 

 

 

 

 

 

0.01

 

 

 

 

 

 

 

$

2.47

 

 

 

 

$

1.64

 

 

 

 

 

Weighted average shares and dilutive securities outstanding

(in thousands):

 

 

 

 

 

 

 

 

 

 

Basic

 

 

102,028

 

 

 

 

 

107,636

 

 

 

 

 

Diluted

 

 

105,354

 

 

 

 

 

114,054

 

 

 

 

 

TENET HEALTHCARE CORPORATION

CONSOLIDATED BALANCE SHEETS

(Unaudited)

 

(Dollars in millions)

 

June 30,

 

December 31,

 

2023

 

2022

ASSETS

 

 

 

 

Current assets:

 

 

 

 

Cash and cash equivalents

 

$

934

 

 

$

858

 

Accounts receivable

 

 

2,914

 

 

 

2,943

 

Inventories of supplies, at cost

 

 

404

 

 

 

405

 

Assets held for sale

 

 

141

 

 

 

 

Other current assets

 

 

1,602

 

 

 

1,775

 

Total current assets

 

 

5,995

 

 

 

5,981

 

Investments and other assets

 

 

3,130

 

 

 

3,147

 

Deferred income taxes

 

 

8

 

 

 

19

 

Property and equipment, at cost, less accumulated depreciation and amortization

 

 

6,268

 

 

 

6,462

 

Goodwill

 

 

10,350

 

 

 

10,123

 

Other intangible assets, at cost, less accumulated amortization

 

 

1,406

 

 

 

1,424

 

Total assets

 

$

27,157

 

 

$

27,156

 

 

 

 

 

 

LIABILITIES AND EQUITY

 

 

 

 

Current liabilities:

 

 

 

 

Current portion of long-term debt

 

$

141

 

 

$

145

 

Accounts payable

 

 

1,246

 

 

 

1,504

 

Accrued compensation and benefits

 

 

718

 

 

 

778

 

Professional and general liability reserves

 

 

257

 

 

 

255

 

Accrued interest payable

 

 

199

 

 

 

213

 

Liabilities held for sale

 

 

17

 

 

 

 

Contract liabilities

 

 

76

 

 

 

110

 

Other current liabilities

 

 

1,498

 

 

 

1,471

 

Total current liabilities

 

 

4,152

 

 

 

4,476

 

Long-term debt, net of current portion

 

 

14,907

 

 

 

14,934

 

Professional and general liability reserves

 

 

793

 

 

 

790

 

Defined benefit plan obligations

 

 

329

 

 

 

331

 

Deferred income taxes

 

 

243

 

 

 

217

 

Other long-term liabilities

 

 

1,732

 

 

 

1,800

 

Total liabilities

 

 

22,156

 

 

 

22,548

 

Commitments and contingencies

 

 

 

 

Redeemable noncontrolling interests in equity of consolidated subsidiaries

 

 

2,277

 

 

 

2,149

 

Equity:

 

 

 

 

Shareholders’ equity:

 

 

 

 

Common stock

 

 

8

 

 

 

8

 

Additional paid-in capital

 

 

4,800

 

 

 

4,778

 

Accumulated other comprehensive loss

 

 

(178

)

 

 

(181

)

Accumulated deficit

 

 

(537

)

 

 

(803

)

Common stock in treasury, at cost

 

 

(2,750

)

 

 

(2,660

)

Total shareholders’ equity

 

 

1,343

 

 

 

1,142

 

Noncontrolling interests

 

 

1,381

 

 

 

1,317

 

Total equity

 

 

2,724

 

 

 

2,459

 

Total liabilities and equity

 

$

27,157

 

 

$

27,156

 

TENET HEALTHCARE CORPORATION

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

 

(Dollars in millions)

 

Six Months Ended

 

June 30,

 

2023

 

2022

Net income

 

$

589

 

 

$

459

 

Adjustments to reconcile net income to net cash provided by operating activities:

 

 

 

 

Depreciation and amortization

 

 

430

 

 

 

419

 

Deferred income tax expense

 

 

37

 

 

 

132

 

Stock-based compensation expense

 

 

33

 

 

 

34

 

Impairment and restructuring charges, and acquisition-related costs

 

 

37

 

 

 

73

 

Litigation and investigation costs

 

 

14

 

 

 

38

 

Net gains on sales, consolidation and deconsolidation of facilities

 

 

(13

)

 

 

 

Loss from early extinguishment of debt

 

 

11

 

 

 

109

 

Equity in earnings of unconsolidated affiliates, net of distributions received

 

 

7

 

 

 

18

 

Amortization of debt discount and debt issuance costs

 

 

18

 

 

 

15

 

Pre-tax income from discontinued operations

 

 

 

 

 

(1

)

Net gains from the sale of investments and long-lived assets

 

 

(15

)

 

 

(71

)

Other items, net

 

 

(3

)

 

 

12

 

Changes in cash from operating assets and liabilities:

 

 

 

 

Accounts receivable

 

 

7

 

 

 

(74

)

Inventories and other current assets

 

 

160

 

 

 

173

 

Income taxes

 

 

(31

)

 

 

(86

)

Accounts payable, accrued expenses, contract liabilities and other current liabilities

 

 

(168

)

 

 

(764

)

Other long-term liabilities

 

 

12

 

 

 

(41

)

Payments for restructuring charges, acquisition-related costs, and litigation costs and settlements

 

 

(78

)

 

 

(98

)

Net cash provided by operating activities

 

 

1,047

 

 

 

347

 

Cash flows from investing activities:

 

 

 

 

Purchases of property and equipment

 

 

(367

)

 

 

(307

)

Purchases of businesses or joint venture interests, net of cash acquired

 

 

(96

)

 

 

(66

)

Proceeds from sales of facilities and other assets

 

 

16

 

 

 

209

 

Proceeds from sales of marketable securities, long-term investments and other assets

 

 

26

 

 

 

9

 

Purchases of marketable securities and equity investments

 

 

(37

)

 

 

(41

)

Other items, net

 

 

(9

)

 

 

(4

)

Net cash used in investing activities

 

 

(467

)

 

 

(200

)

Cash flows from financing activities:

 

 

 

 

Repayments of borrowings

 

 

(1,437

)

 

 

(2,744

)

Proceeds from borrowings

 

 

1,362

 

 

 

2,013

 

Repurchases of common stock

 

 

(90

)

 

 

 

Debt issuance costs

 

 

(15

)

 

 

(24

)

Distributions paid to noncontrolling interests

 

 

(270

)

 

 

(310

)

Proceeds from the sale of noncontrolling interests

 

 

30

 

 

 

9

 

Purchases of noncontrolling interests

 

 

(79

)

 

 

(29

)

Other items, net

 

 

(5

)

 

 

(75

)

Net cash used in financing activities

 

 

(504

)

 

 

(1,160

)

Net increase (decrease) in cash and cash equivalents

 

 

76

 

 

 

(1,013

)

Cash and cash equivalents at beginning of period

 

 

858

 

 

 

2,364

 

Cash and cash equivalents at end of period

 

$

934

 

 

$

1,351

 

Supplemental disclosures:

 

 

 

 

Interest paid, net of capitalized interest

 

$

(445

)

 

$

(416

)

Income tax payments, net

 

$

(158

)

 

$

(140

)

TENET HEALTHCARE CORPORATION

SEGMENT REPORTING

(Unaudited)

 

 

 

Three Months Ended

 

Six Months Ended

 

 

June 30,

 

June 30,

(Dollars in millions)

 

2023

 

2022

 

2023

 

2022

Net operating revenues:

 

 

 

 

 

 

 

 

Ambulatory Care

 

$

942

 

 

$

771

 

 

$

1,847

 

 

$

1,509

 

Hospital Operations and other (prior to inter-segment eliminations)

 

 

3,922

 

 

 

3,645

 

 

 

7,821

 

 

 

7,443

 

Conifer

 

 

 

 

 

 

 

 

Tenet

 

 

105

 

 

 

111

 

 

 

212

 

 

 

226

 

Other clients

 

 

218

 

 

 

222

 

 

 

435

 

 

 

431

 

Total Conifer revenues

 

 

323

 

 

 

333

 

 

 

647

 

 

 

657

 

Inter-segment eliminations

 

 

(105

)

 

 

(111

)

 

 

(212

)

 

 

(226

)

Total

 

$

5,082

 

 

$

4,638

 

 

$

10,103

 

 

$

9,383

 

 

 

 

 

 

 

 

 

 

Equity in earnings of unconsolidated affiliates:

 

 

 

 

 

 

 

 

Ambulatory Care

 

$

52

 

 

$

52

 

 

$

99

 

 

$

94

 

Hospital Operations and other

 

 

2

 

 

 

2

 

 

 

5

 

 

 

6

 

Total

 

$

54

 

 

$

54

 

 

$

104

 

 

$

100

 

 

 

 

 

 

 

 

 

 

Adjusted EBITDA (including grant income):

 

 

 

 

 

 

 

 

Ambulatory Care

 

$

370

 

 

$

319

 

 

$

710

 

 

$

601

 

Hospital Operations and other

 

 

388

 

 

 

431

 

 

 

793

 

 

 

945

 

Conifer

 

 

85

 

 

 

93

 

 

 

172

 

 

 

185

 

Total

 

$

843

 

 

$

843

 

 

$

1,675

 

 

$

1,731

 

 

 

 

 

 

 

 

 

 

Adjusted EBITDA margins (including grant income):

 

 

 

 

 

 

 

 

Ambulatory Care

 

 

39.3

%

 

 

41.4

%

 

 

38.4

%

 

 

39.8

%

Hospital Operations and other

 

 

9.9

%

 

 

11.8

%

 

 

10.1

%

 

 

12.7

%

Conifer

 

 

26.3

%

 

 

27.9

%

 

 

26.6

%

 

 

28.2

%

Total

 

 

16.6

%

 

 

18.2

%

 

 

16.6

%

 

 

18.4

%

 

 

 

 

 

 

 

 

 

Adjusted EBITDA margins (excluding grant income):

 

 

 

 

 

 

 

 

Ambulatory Care

 

 

39.2

%

 

 

41.1

%

 

 

38.4

%

 

 

39.6

%

Hospital Operations and other

 

 

9.7

%

 

 

9.3

%

 

 

10.0

%

 

 

11.4

%

Conifer

 

 

26.3

%

 

 

27.9

%

 

 

26.6

%

 

 

28.2

%

Total

 

 

16.4

%

 

 

16.1

%

 

 

16.5

%

 

 

17.4

%

 

 

 

 

 

 

 

 

 

Capital expenditures:

 

 

 

 

 

 

 

 

Ambulatory Care

 

$

20

 

 

$

19

 

 

$

38

 

 

$

40

 

Hospital Operations and other

 

 

109

 

 

 

130

 

 

 

324

 

 

 

262

 

Conifer

 

 

3

 

 

 

3

 

 

 

5

 

 

 

5

 

Total

 

$

132

 

 

$

152

 

 

$

367

 

 

$

307

 

TENET HEALTHCARE CORPORATION

Additional Supplemental Non-GAAP disclosures

Table #1 – Reconciliations of Net Income Available to Tenet Healthcare Corporation Common Shareholders to Adjusted Net Income Available from Continuing Operations to Common Shareholders

(Unaudited)

 

 

 

Three Months Ended

 

Six Months Ended

 

 

June 30,

 

June 30,

(Dollars in millions, except per share amounts)

 

2023

 

2022

 

2023

 

2022

Net income available to Tenet Healthcare Corporation common shareholders

 

$

123

 

 

$

38

 

 

$

266

 

 

$

178

 

Net income from discontinued operations

 

 

 

 

 

 

 

 

 

 

 

1

 

Net income from continuing operations

 

 

123

 

 

 

38

 

 

 

266

 

 

 

177

 

Less: Impairment and restructuring charges, and acquisition-related costs

 

 

(16

)

 

 

(57

)

 

 

(37

)

 

 

(73

)

Litigation and investigation costs

 

 

(10

)

 

 

(18

)

 

 

(14

)

 

 

(38

)

Net gains on sales, consolidation and deconsolidation of facilities

 

 

 

 

 

1

 

 

 

13

 

 

 

 

Loss from early extinguishment of debt

 

 

(11

)

 

 

(66

)

 

 

(11

)

 

 

(109

)

Tax and noncontrolling interests impact of above items

 

 

6

 

 

 

17

 

 

 

7

 

 

 

26

 

Adjusted net income available from continuing operations to common shareholders

 

$

154

 

 

$

161

 

 

$

308

 

 

$

371

 

 

 

 

 

 

 

 

 

 

Diluted earnings per share from continuing operations

 

$

1.15

 

 

$

0.35

 

 

$

2.47

 

 

$

1.63

 

Less: Impairment and restructuring charges, and acquisition-related costs

 

 

(0.15

)

 

 

(0.52

)

 

 

(0.35

)

 

 

(0.64

)

Litigation and investigation costs

 

 

(0.10

)

 

 

(0.17

)

 

 

(0.13

)

 

 

(0.33

)

Net gains on sales, consolidation and deconsolidation of facilities

 

 

 

 

 

0.01

 

 

 

0.12

 

 

 

 

Loss from early extinguishment of debt

 

 

(0.10

)

 

 

(0.61

)

 

 

(0.10

)

 

 

(0.96

)

Tax and noncontrolling interests impact of above items

 

 

0.06

 

 

 

0.16

 

 

 

0.06

 

 

 

0.23

 

Adjusted diluted earnings per share from continuing operations

 

$

1.44

 

 

$

1.48

 

 

$

2.87

 

 

$

3.33

 

 

 

 

 

 

 

 

 

 

Weighted average basic shares outstanding (in thousands)

 

 

101,766

 

 

 

107,790

 

 

 

102,028

 

 

 

107,636

 

Weighted average dilutive shares outstanding (in thousands)

 

 

104,778

 

 

 

108,750

 

 

 

105,354

 

 

 

114,054

 

TENET HEALTHCARE CORPORATION

Additional Supplemental Non-GAAP disclosures

Table #2 – Reconciliations of Net Income Available to Tenet Healthcare Corporation Common Shareholders to Adjusted EBITDA

(Unaudited)

 

 

 

Three Months Ended

 

Six Months Ended

 

 

June 30,

 

June 30,

(Dollars in millions)

 

2023

 

2022

 

2023

 

2022

Net income available to Tenet Healthcare Corporation common shareholders

 

$

123

 

 

$

38

 

 

$

266

 

 

$

178

 

Less: Net income available to noncontrolling interests

 

 

(170

)

 

 

(141

)

 

 

(323

)

 

 

(281

)

Income from discontinued operations, net of tax

 

 

 

 

 

 

 

 

 

 

 

1

 

Income from continuing operations

 

 

293

 

 

 

179

 

 

 

589

 

 

 

458

 

Income tax expense

 

 

(80

)

 

 

(86

)

 

 

(164

)

 

 

(185

)

Loss from early extinguishment of debt

 

 

(11

)

 

 

(66

)

 

 

(11

)

 

 

(109

)

Other non-operating income, net

 

 

6

 

 

 

 

 

 

4

 

 

 

 

Interest expense

 

 

(226

)

 

 

(222

)

 

 

(447

)

 

 

(449

)

Operating income

 

 

604

 

 

 

553

 

 

 

1,207

 

 

 

1,201

 

Litigation and investigation costs

 

 

(10

)

 

 

(18

)

 

 

(14

)

 

 

(38

)

Net gains on sales, consolidation and deconsolidation of facilities

 

 

 

 

 

1

 

 

 

13

 

 

 

 

Impairment and restructuring charges, and acquisition-related costs

 

 

(16

)

 

 

(57

)

 

 

(37

)

 

 

(73

)

Depreciation and amortization

 

 

(213

)

 

 

(216

)

 

 

(430

)

 

 

(419

)

Adjusted EBITDA

 

$

843

 

 

$

843

 

 

$

1,675

 

 

$

1,731

 

 

 

 

 

 

 

 

 

 

Net operating revenues

 

$

5,082

 

 

$

4,638

 

 

$

10,103

 

 

$

9,383

 

 

 

 

 

 

 

 

 

 

Net income available to Tenet Healthcare Corporation common shareholders as a % of net operating revenues

 

 

2.4

%

 

 

0.8

%

 

 

2.6

%

 

 

1.9

%

 

 

 

 

 

 

 

 

 

Adjusted EBITDA as a % of net operating revenues (Adjusted EBITDA margin)

 

 

16.6

%

 

 

18.2

%

 

 

16.6

%

 

 

18.4

%

TENET HEALTHCARE CORPORATION

Additional Supplemental Non-GAAP disclosures

Table #3 – Reconciliations of Net Cash Provided by Operating Activities to Free Cash Flow and Adjusted Free Cash Flow from Continuing Operations

(Unaudited)

 

(Dollars in millions)

 

2023

 

Q2

 

YTD

Net cash provided by operating activities

 

$

598

 

 

$

1,047

 

Purchases of property and equipment

 

 

(132

)

 

 

(367

)

Free cash flow – continuing operations

 

$

466

 

 

$

680

 

 

 

 

 

 

Net cash used in investing activities

 

$

(181

)

 

$

(467

)

Net cash used in financing activities

 

$

(249

)

 

$

(504

)

 

 

 

 

 

Net cash provided by operating activities

 

$

598

 

 

$

1,047

 

Less: Payments for restructuring charges, acquisition-related costs, and litigation costs and settlements

 

 

(54

)

 

 

(78

)

Adjusted net cash provided by operating activities from continuing operations

 

 

652

 

 

 

1,125

 

Purchases of property and equipment

 

 

(132

)

 

 

(367

)

Adjusted free cash flow – continuing operations

 

$

520

 

 

$

758

 

 

(Dollars in millions)

 

2022

 

Q2

 

YTD

Net cash provided by operating activities

 

$

119

 

 

$

347

 

Purchases of property and equipment

 

 

(152

)

 

 

(307

)

Free cash flow

 

 

(33

)

 

 

40

 

Add back: Medicare Advance Repayments

 

 

281

 

 

 

475

 

Free cash flow – continuing operations, excluding repayments of Medicare Advances

 

$

248

 

 

$

515

 

 

 

 

 

 

Net cash used in investing activities

 

$

(140

)

 

$

(200

)

Net cash used in financing activities

 

$

(33

)

 

$

(1,160

)

 

 

 

 

 

Net cash provided by operating activities

 

$

119

 

 

$

347

 

Less: Payments for restructuring charges, acquisition-related costs, and litigation costs and settlements

 

 

(42

)

 

 

(98

)

Adjusted net cash provided by operating activities from continuing operations

 

 

161

 

 

 

445

 

Purchases of property and equipment

 

 

(152

)

 

 

(307

)

Adjusted free cash flow – continuing operations

 

 

9

 

 

 

138

 

Add back: Medicare Advance Repayments

 

 

281

 

 

 

475

 

Adjusted free cash flow – continuing operations, excluding repayments of Medicare Advances

 

$

290

 

 

$

613

 

TENET HEALTHCARE CORPORATION

Additional Supplemental Non-GAAP disclosures

Table #4 – Reconciliations of Outlook Net Income Available to Tenet Healthcare Corporation Common Shareholders to Outlook Adjusted Net Income Available from Continuing Operations to Common Shareholders

(Unaudited)

 

 

 

Third Quarter 2023

 

FY 2023

(Dollars in millions, except per share amounts)

 

Low

 

High

 

Low

 

High

Net income available to Tenet Healthcare Corporation common shareholders

 

$

75

 

 

$

120

 

 

$

447

 

 

$

582

 

Less: Impairment and restructuring charges, acquisition-related costs, and litigation costs and settlements(1)

 

 

(30

)

 

 

(20

)

 

 

(125

)

 

 

(75

)

Net gains on sales, consolidation and deconsolidation of facilities

 

 

 

 

 

 

 

 

13

 

 

 

13

 

Loss from early extinguishment of debt(2)

 

 

 

 

 

 

 

 

(11

)

 

 

(11

)

Tax and noncontrolling interests impact of above items

 

 

5

 

 

 

5

 

 

 

20

 

 

 

15

 

Adjusted net income available from continuing operations to common shareholders

 

$

100

 

 

$

135

 

 

$

550

 

 

$

640

 

 

 

 

 

 

 

 

 

 

Diluted earnings per share from continuing operations

 

$

0.71

 

 

$

1.13

 

 

$

4.19

 

 

$

5.48

 

Less: Impairment and restructuring charges, acquisition-related costs, and litigation costs and settlements

 

 

(0.28

)

 

 

(0.20

)

 

 

(1.20

)

 

 

(0.71

)

Net gains on sales, consolidation and deconsolidation of facilities

 

 

 

 

 

 

 

 

0.12

 

 

 

0.12

 

Loss from early extinguishment of debt

 

 

 

 

 

 

 

 

(0.10

)

 

 

(0.10

)

Tax and noncontrolling interests impact of above items

 

 

0.05

 

 

 

0.05

 

 

 

0.19

 

 

 

0.14

 

Adjusted diluted earnings per share from continuing operations

 

$

0.94

 

 

$

1.28

 

 

$

5.18

 

 

$

6.03

 

 

 

 

 

 

 

 

 

 

Weighted average basic shares outstanding (in thousands)

 

 

102,000

 

 

 

102,000

 

 

 

102,000

 

 

 

102,000

 

Weighted average dilutive shares outstanding (in thousands)

 

 

105,000

 

 

 

105,000

 

 

 

105,000

 

 

 

105,000

 

(1)

The figures shown represent the Company's estimate for restructuring charges plus the actual year-to-date results for impairment and restructuring charges, acquisition-related costs, and litigation costs and settlements. The Company does not generally forecast impairment charges, acquisition-related costs, and litigation costs and settlements because it does not believe that it can forecast these items with sufficient accuracy since some of these items are indeterminable at the time the Company provides its financial Outlook.

(2)

The Company does not generally forecast losses from the early extinguishment of debt because the Company does not believe that it can forecast this item with sufficient accuracy since it is indeterminable at the time the Company provides its financial Outlook. The figures shown relate to the debt repurchased or refinanced by the Company in 2023.

TENET HEALTHCARE CORPORATION

Additional Supplemental Non-GAAP disclosures

Table #5 – Reconciliations of Outlook Net Income Available to Tenet Healthcare Corporation Common Shareholders to Outlook Adjusted EBITDA

(Unaudited)

 

 

 

Third Quarter 2023

 

FY 2023

(Dollars in millions)

 

Low

 

High

 

Low

 

High

Net income available to Tenet Healthcare Corporation common shareholders

 

$

75

 

 

$

120

 

 

$

447

 

 

$

582

 

Less: Net income available to noncontrolling interests

 

 

(160

)

 

 

(170

)

 

 

(660

)

 

 

(700

)

Income tax expense

 

 

(65

)

 

 

(75

)

 

 

(315

)

 

 

(335

)

Interest expense

 

 

(230

)

 

 

(220

)

 

 

(905

)

 

 

(895

)

Loss from early extinguishment of debt(2)

 

 

 

 

 

 

 

 

(11

)

 

 

(11

)

Other non-operating income (expense), net

 

 

(5

)

 

 

 

 

 

(10

)

 

 

 

Net gains on sales, consolidation and deconsolidation of facilities

 

 

 

 

 

 

 

 

13

 

 

 

13

 

Impairment and restructuring charges, acquisition-related costs, and litigation costs and settlements(1)

 

 

(30

)

 

 

(20

)

 

 

(125

)

 

 

(75

)

Depreciation and amortization

 

 

(210

)

 

 

(220

)

 

 

(850

)

 

 

(875

)

Adjusted EBITDA

 

$

775

 

 

$

825

 

 

$

3,310

 

 

$

3,460

 

 

 

 

 

 

 

 

 

 

Income from continuing operations

 

$

75

 

 

$

120

 

 

$

447

 

 

$

582

 

Net operating revenues

 

$

4,900

 

 

$

5,100

 

 

$

20,100

 

 

$

20,500

 

Net income available to Tenet Healthcare Corporation common shareholders as a % of net operating revenues

 

 

1.5

%

 

 

2.4

%

 

 

2.2

%

 

 

2.8

%

Adjusted EBITDA as a % of net operating revenues (Adjusted EBITDA margin)

 

 

15.8

%

 

 

16.2

%

 

 

16.5

%

 

 

16.9

%

(1)

The figures shown represent the Company's estimate for restructuring charges plus the actual year-to-date results for impairment and restructuring charges, acquisition-related costs, and litigation costs and settlements. The Company does not generally forecast impairment charges, acquisition-related costs, and litigation costs and settlements because it does not believe that it can forecast these items with sufficient accuracy since some of these items are indeterminable at the time the Company provides its financial Outlook.

(2)

The Company does not generally forecast losses from the early extinguishment of debt because the Company does not believe that it can forecast this item with sufficient accuracy since it is indeterminable at the time the Company provides its financial Outlook. The figures shown relate to the debt repurchased or refinanced by the Company in 2023.

TENET HEALTHCARE CORPORATION

Additional Supplemental Non-GAAP disclosures

Table #6 – Reconciliations of Outlook Net Cash Provided by Operating Activities

to Outlook Free Cash Flow Continuing Operations and Outlook Adjusted Free Cash

Flow Continuing Operations

(Unaudited)

 

(Dollars in millions)

 

FY 2023

 

 

Low

 

High

Net cash provided by operating activities

 

$

1,775

 

 

$

2,075

 

Purchases of property and equipment

 

 

(675

)

 

 

(725

)

Free cash flow – continuing operations

 

$

1,100

 

 

$

1,350

 

 

 

 

 

 

Net cash provided by operating activities

 

$

1,775

 

 

$

2,075

 

Less: Payments for restructuring charges, acquisition-related costs and litigation costs and settlements(1)

 

 

(150

)

 

 

(100

)

Adjusted net cash provided by operating activities – continuing operations

 

 

1,925

 

 

 

2,175

 

Purchases of property and equipment

 

 

(675

)

 

 

(725

)

Adjusted free cash flow – continuing operations(2)

 

$

1,250

 

 

$

1,450

(1)

The figures shown represent the Company's estimate for restructuring payments plus the actual year-to-date payments for restructuring charges, acquisition-related costs, and litigation costs and settlements. The Company does not generally forecast payments for acquisition-related costs, and litigation costs and settlements because it does not believe that it can forecast these items with sufficient accuracy since some of these items are indeterminable at the time the Company provides its financial Outlook.

(2)

The Company’s definition of Adjusted Free Cash Flow does not include other important uses of cash including (1) cash used to purchase businesses or joint venture interests, or (2) any items that are classified as Cash Flows From Financing Activities on the Company’s Consolidated Statement of Cash Flows, including items such as (i) cash used to repay borrowings, and (ii) distributions paid to noncontrolling interests.

 

Investor Contact

Will McDowell

469-893-2387

william.mcdowell@tenethealth.com

Media Contact

Robert Dyer

469-893-2640

mediarelations@tenethealth.com

Source: Tenet Healthcare Corporation

FAQ

What was the net income from continuing operations in Q2 2023?

The net income from continuing operations in Q2 2023 was $123 million.

What was the Consolidated Adjusted EBITDA in Q2 2023?

The Consolidated Adjusted EBITDA in Q2 2023 was $843 million.

What is the updated FY 2023 Adjusted EBITDA Outlook?

The updated FY 2023 Adjusted EBITDA Outlook is expected to be in the range of $3.310 billion to $3.460 billion.

Tenet Healthcare Corporation New

NYSE:THC

THC Rankings

THC Latest News

THC Stock Data

14.14B
93.21M
1.17%
96.73%
2.53%
Medical Care Facilities
Pharmaceutical Preparations
Link
United States of America
CHAPEL HILL